Azithromycin Reverses Airflow Obstruction in Established Bronchiolitis Obliterans Syndrome
- 15 September 2005
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 172 (6), 772-775
- https://doi.org/10.1164/rccm.200411-1537oc
Abstract
Introduction: A recent pilot study noted clinical benefit of macrolide therapy in the management of six lung transplant recipients with bronchiolitis obliterans syndrome (BOS), a condition previously regarded as irreversible. Objective: To examine the effect of low-dose macrolides on lung function in lung allograft recipients with established BOS and to assess whether this benefit is sustained. Methods: We retrospectively evaluated the effect of azithromycin (250 mg alternate days) on clinical status and lung function in 20 allograft recipients with established BOS, confirmed by decline in FEV1 or FEF25–75; consistent high-resolution computed tomography findings; and exclusion of acute rejection, infection, or anastomatic complications. Azithromycin was introduced at mean 82 months after transplantation. BOS staging at initiation of treatment was BOS 3 (10), BOS 2 (2), BOS 1 (6), and BOS0-p (2). All patients were on maintenance immunosuppression comprising cell-cycle inhibitor, oral corticosteroids, and calcineurin inhibitor. Results: There was a significant increase in FEV1 of median 110 ml (range, −70 to 730 ml) between baseline and 3 months of azithromycin therapy (p = 0.002). This improvement was sustained beyond 3 months in the majority of patients, who had initially benefited from azithromycin (up to 11 months follow up). Conclusions: This case series confirms the benefit of azithromycin in not only halting, but reversing the declining lung function seen in patients with BOS. This benefit appears to be maintained over time. Low-dose macrolides offer a new and exciting therapeutic strategy for the treatment of progressive BOS, and further clinical and translational mechanistic studies are required.This publication has 35 references indexed in Scilit:
- Clarithromycin has a preventive effect on chronic rejection by downregulation of innate immunity and mesenchymal growthThe Journal of Heart and Lung Transplantation, 2005
- Azithromycin reverses airflow obstruction in established Bronchiolitis Obliterans Syndrome (BOS) following lung transplantationThe Journal of Heart and Lung Transplantation, 2005
- Superiority of voriconazole over amphotericin B in the treatment of invasive aspergillosis after heart transplantationThe Journal of Heart and Lung Transplantation, 2005
- Reticular basement membrane thickening in airways of lung transplant recipients is not affected by inhaled corticosteroidsClinical & Experimental Allergy, 2004
- Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosisJournal of Antimicrobial Chemotherapy, 2004
- Bronchoalveolar lavage macrophage and lymphocyte phenotypes in lung transplant recipientsThe Journal of Heart and Lung Transplantation, 2001
- Azithromycin Inhibits Quorum Sensing in Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2001
- Lung TransplantationThe New England Journal of Medicine, 1999
- Differential effects of cyclosporin A and tacrolimus on the production of TGF-β: implications for the development of obliterative bronchiolitis after lung transplantationTransplant International, 1998
- Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-kappa(B). Implications for FK506 nephropathy.JCI Insight, 1996